Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
04/2010
04/01/2010WO2009071993A3 Pharmaceutical compositon for cleansing of the bowel
04/01/2010WO2009037592A3 Triazole-based aminoglycoside-peptide conjugates and methods of use
04/01/2010US20100083393 Method of constructing clone mammal
04/01/2010US20100081718 Combinations comprising alpha-2-delta ligands
04/01/2010US20100081696 Fluoro substituted cycloalkanoindoles, compositions containing such compounds and methods of treatment
04/01/2010US20100081639 Pharmaceutical composition comprising fermented ginseng
04/01/2010US20100080819 Modulators of p-selectin glycoprotein ligand 1
04/01/2010US20100080782 Use of probiotic lactic acid bacteria for balancing the skin's immune system
04/01/2010US20100080778 Stem cell expansion enhancing factor and method of use
04/01/2010CA2738599A1 Immunostimulant compositions comprising a nucleobase and a polysaccharide obtainable from fungi, yeast or bacteria
04/01/2010CA2738195A1 Spy1a as a diagnostic and prognostic marker of cancer
03/2010
03/31/2010EP2169060A1 Novel polypeptide useful for diagnosis and treatment of cancer
03/31/2010EP2168966A1 Bicycloaniline derivative
03/31/2010EP2168600A1 Therapeutic or prophylactic agent for cerebral aneurysm
03/31/2010EP2168598A1 Method of Treatment Using Ligand-Immunogen Conjugates
03/31/2010EP2168581A2 Stable polymorph of N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof
03/31/2010EP2168577A1 Drug having effect of promoting hepatocyte growth
03/31/2010EP2167648A1 Methods and compositions for optimized expansion and implantation of mesenchymal stem cells
03/31/2010EP2167522A2 Triazole-based aminoglycoside-peptide conjugates and methods of use
03/31/2010EP2167132A1 Resuscitation fluid
03/31/2010EP2167131A1 Coating formulations including polyphosphazene polyelectrolytes and biologically active agents and asperities coated with such formulations
03/31/2010EP2167102A2 Use of hyaluronic acid for preparing compositions particularly for improving the function of skin, eye and mucous membrane protection
03/31/2010EP2167099A2 Treatment of pulmonary hypertension with carbonic anhydrase inhibitors in combination with a sympathomimetic amine
03/31/2010EP2167062A1 Compositions and uses comprising a retinoid compound, an anti-irritant compound and benzoyl peroxide in acne
03/31/2010EP2166862A2 Compositions and methods for cell killing
03/31/2010EP1530724B1 Diagnosis and prevention of cancer cell invasion
03/31/2010EP1333823B1 Therapeutic use of aerosolized s-nitrosoglutathione in cystic fibrosis
03/31/2010EP1223923B1 Unsaturated aryl sulfones for protecting normal cells from cytotoxicity of chemotherapeutic agents
03/31/2010EP1194168B1 Methods and products for manipulating uncoupling protein expression
03/31/2010CN101688327A Serpine1 polymorphisms are predictive of response to activated protein c administration and risk of death
03/31/2010CN101687104A Cancer treatment combination therapy comprising vinflunine and trastuzumab
03/31/2010CN101687044A Formulations for the oral administration of therapeutic agents and related methods
03/31/2010CN101687041A N-halogenated amino acid formulations with anti-inflammatory compounds
03/31/2010CN101687036A CHK1 inhibitors with b cell depleting antibodies for the treatment of hematologic malignancies
03/31/2010CN101687034A Remedy for chemotherapy-resistant cancer containing hla class i-recognizing antibody as the active ingredient and use of the same
03/31/2010CN101687011A New treatment for chemical substance addiction
03/31/2010CN101687008A Therapeutic agent and detection reagent for arteriosclerotic disease which targets for thallusin
03/31/2010CN101686985A Cytotoxic t cell activator comprising ep4 agonist
03/31/2010CN101686984A Pharmaceutical combination of nsaid and prostaglandin compound
03/31/2010CN101686970A Synergistic combination of anthranilamide pyridinureas and benzamide derivatives
03/31/2010CN101686962A Anthelmintic combination
03/31/2010CN101686960A Methods and compositions for contributing to the treatment of cancers
03/31/2010CN101686959A Combination therapy with a compound acting as a platelet ADP receptor inhibitor
03/31/2010CN101686951A selective proteasome inhibitors for treating diabetes
03/31/2010CN101684499A Compositions and methods for detection and treatment of proliferative abnormalities associated with overexpression of human transketolase like-1 gene
03/31/2010CN101684091A cannabinoid receptor ligands
03/31/2010CN101683531A Novel ppar ligands that do not cause fluid retention, edema or congestive heart failure
03/31/2010CN101683530A Novel ppar ligands that do not cause fluid retention, edema or congestive heart failure
03/31/2010CN101683529A Novel ppar ligands that do not cause fluid retention, edema or congestive heart failure
03/31/2010CN101683528A Novel ppar ligands that do not cause fluid retention, edema or congestive heart failure
03/31/2010CN101683527A Compound preparation for treating cold and preparation method thereof
03/31/2010CN101683526A Pharmaceutical composition containing angiotensin II receptor antagonist, B vitamins and gingo biloba extract
03/31/2010CN101683525A Treatment of fungal infections with polyene or beta glucan synthase inhibitor antifungals combined with anti hsp90 antibodies
03/31/2010CN101683520A Methods for treating tweak-related conditions
03/31/2010CN101683347A Topical preparation containing pazufloxacin and steroidal anti-inflammatory drugs
03/31/2010CN101683334A (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
03/31/2010CN101683317A 缓释组合物 Sustained release composition
03/30/2010US7687502 Substituted quinazoline or pyridopyrimidine derivative
03/30/2010US7687489 Agent for treatment of cerebral ischemic diseases
03/30/2010US7687485 Formulation for menopausal women
03/30/2010US7687483 Phosphorus compounds used for improving permeability of drugs such as anticarcinogenic agents to biological barriers; drug delivery
03/30/2010US7687273 Method for producing purified hematinic iron-saccharidic complex and product produced
03/30/2010US7687075 Colonic purgative composition with soluble binding agent
03/30/2010US7687074 Prevent adhesion of pathogens; mixture containing fatty acid, or glycerides thereof
03/30/2010US7687059 Systems and methods for treating patients with processed lipoaspirate cells
03/30/2010CA2496121C Stable formulations of hyaluronic acid for use in the therapeutic treatment of arthropathy
03/30/2010CA2453312C Therapeutic agent delivery tampon
03/30/2010CA2438651C Mucoadhesive, disintegratable medicinal preparation for active substance administration in veterinary and human medicine
03/30/2010CA2433069C Latent human tuberculosis model, diagnostic antigens, and methods of use
03/30/2010CA2412205C Medicinal product package for eradication therapy
03/30/2010CA2395789C Methods of detection of amyloidogenic proteins
03/30/2010CA2380451C Primary composition containing a lipophilic bioactive compound
03/30/2010CA2360685C Methods for restoring and/or enhancing accommodation in pseudo phakia
03/30/2010CA2355860C Dosage forms comprising porous particles
03/30/2010CA2241604C Mesothelium antigen and methods and kits for targeting it
03/30/2010CA2171207C Methods for regulating gastrointestinal motility
03/25/2010WO2010033443A1 Combination of hcv ns3 protease inhibitor with interferon and ribavirin
03/25/2010WO2010032816A1 Novel lysophosphatidylserine receptor
03/25/2010WO2010032786A1 Transgenic animal
03/25/2010WO2010032764A1 Therapeutic/prophylactic agent for prostate cancer
03/25/2010WO2010032696A1 Diagnosis method and therapeutic method for cancer
03/25/2010WO2010032266A2 Novel single unit carbapenem aminoglycoside formulations
03/25/2010WO2010032054A1 Craving reduction
03/25/2010WO2010031832A2 Synergistic combinations of a macrocyclic inhibitor of hcv and a thiophene-2-carboxylic acid derivative
03/25/2010WO2010031825A2 Methods and compositions for the treatment of cancer
03/25/2010WO2010012687A3 Preparations based on artemisia annua, the conversion thereof into microparticles and nanoparticles, and use of same
03/25/2010WO2009137074A9 Compositions and methods for treating diabetic ulcers
03/25/2010US20100076256 Cardiac disease treatment and device
03/25/2010US20100076174 ErbB Interface Peptidomimetics And Methods Of Use Thereof
03/25/2010US20100076073 Combination of an NMDA receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders
03/25/2010US20100075945 Gram-positive carbapenem antibacterials and processes for their preparation
03/25/2010US20100075938 Use of Chemical Chelators as Reversal Agents for Drug-Induced Neuromuscular Block
03/25/2010US20100074877 Composition for improving skin quality and a process for preparing the same
03/25/2010US20100074870 Probiotic infant products
03/25/2010DE102008047515A1 Use of histone deacetylase inhibitor for the preparation of a medicament for prophylaxis and/or treatment of demyelinating disease, preferably autoimmune neuropathy, Guillain-Barre syndrome, acute inflammatory demyelinating polyneuropathy
03/25/2010CA2737551A1 Methods and compositions for the treatment of cancer
03/25/2010CA2737376A1 Combination of hcv ns3 protease inhibitor with interferon and ribavirin
03/24/2010EP2166095A2 Antisense oligonucleotides capable of inhibiting the formation of capillary tubes in endothelial cells
03/24/2010EP2165716A1 Novel bone mass increasing agent
03/24/2010EP2165715A1 Therapeutic agent for cancer, and method for treatment of cancer
1 ... 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 ... 1151